Recombinant Lys-Plasminogen Given Before, but Not After, Recombinant Tissue-Type Plasminogen Activator Markedly Improves Coronary Thrombolysis in Dogs: Relationship of Thrombolytic Efficacy with Parameters of Fibrinolysis

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 2, 1996, Pages 283-289

  Chen, L Y ^a   Nichols, W W ^a   Saldeen, T G P ^a   Mehta, J L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Coronary thrombolysis; Lys plasminogen; Tissue type plasminogen activator

Indexed keywords

PLASMINOGEN[LYSINE]; RECOMBINANT PLASMINOGEN ACTIVATOR; TISSUE PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; BLOOD FLOW VELOCITY; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY THROMBOSIS; DOG; DRUG EFFECT; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; LEFT ANTERIOR DESCENDING CORONARY ARTERY; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ANIMALS; ANTIFIBRINOLYTIC AGENTS; CORONARY THROMBOSIS; DOGS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FIBRINOLYSIS; MALE; PEPTIDE FRAGMENTS; PLASMINOGEN; PLASMINOGEN ACTIVATORS; REPERFUSION; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0030050102     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199602000-00016     Document Type: Article

References (42)

1. Rijken DC, Haylaverts M, Collen D. Fibrinolytic properties of one-chain and two-chain human extrinsic (tissue-type) plasminogen activator. J Biol Chem 1982;257:2920-5.
2. Matsuo O, Rijken DC, Collen D. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro. Thromb Haemost 1981;45:225-9.
3. Gold HK, Leinbach RC, Garabedian HD, et al. Acute coronary reocclusion after thrombolysis with recombinant human tissue-type plasminogen activator. Prevention by a maintenance infusion. Circulation 1986;73:347-52.
4. The TIMI Study group. The thrombolysis in myocardial infarction (TIMI) trial: phase I findings. N Engl J Med 1985; 312:932-6.
5. Armstrong PW, Baigrie RS, Daly PA. Tissue plasminogen activator Toronto (TPAT) placebo-controlled randomized trial in acute myocardial infarction. J Am Coll Cardiol 1989; 13:1469-76.
6. Nicolini FA, Mehta JL, Nichols WW, Saldeen TGP, Grant M. Prostacyclin analog iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation 1990;81:1115-22.
7. Mehta JL, Nicolini FA, Nichols WW, Saldeen TGP. Concurrent nitroglycerin administration decreases thrombolytic potential of tissue-type plasminogen activator. J Am Coll Cardiol 1991;17:805-11.
8. Nicolini FA, Nichols WW, Mehta JL, et al. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue plasminogen activator. J Am Coll Cardiol 1992;20: 228-35.
9. Nicolini FA, Nichols WW, Saldeen TGP, Khan S, Mehta JL. Adjunctive therapy with low molecular weight heparin with t-PA causes sustained reflow in canine coronary thrombosis. Am Heart J 1992;124:280-8.
10. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine, a model for in vivo evaluation of anti-thrombotic agents. Thromb Res 1980;17:841-53.
11. 2- prostaglandin endoperoxide receptor activation in vivo. J Clin Invest 1986;77:496-502.
12. Suenson E, Petersen LC. Fibrin and plasminogen structures essential to stimulation of plasmin formation by tissue-type plasminogen activator. Biochim Biophys Acta 1986;870: 510-9.
13. de Vries, Veerman H, Koornneef E, Pannekoek H. Tissue- type plasminogen activator and its substrate glu-plasminogen share common binding sites in limited plasmin- digested fibrin. J Biol Chem 1990;265:13547-52.
14. Tilsner V, Witte G. Effectiveness of intra-arterial plasminogen application in combination with percutaneous transluminal angioplasty (PTA) or catheter assisted lysis (CT) in patients with chronic peripheral occlusive disease of the lower limits (POL). Haemostasis 1988;18(suppl 1):139-56.
15. Kakkar VV, Scully MF. Intermittent plasminogen streptokinase treatment of deep vein thrombosis. Haemostasis 1988; 18(suppl 1):127-38.
16. Anderle K, Frohlich A. Review of studies with plasminogen concentrates and proposals for further strategies with plasminogen concentrates. Haemostasis 1988;18(suppl 1):165- 75.
17. Suenson E, Thorsen S. Secondary site binding of glu- plasminogen, lys-plasmin and miniplasmin to fibrin. Biochem J 1981;197:619-28.
18. Suenson E, Lutzen O, Thorsen S. Initial plasmin degradation of fibrin as the basis of a positive feedback mechanism in fibrinolysis. Eur J Biochem 1984;140:513-22.
19. Fredenburgh JC, Nesheim ME. Lys-plasminogen is a significant intermediate in the activation of glu-plasminogen during fibrinolysis in vitro. J Biol Chem 1992;267:26150-6.
20. Badylak SF, Voytik SL, Henkin J, Burke S, Sasahara AA, Simmons A. The beneficial effect of lys-plasminogen upon the thrombolytic efficacy of urokinase in dog model of peripheral arterial thrombosis. Haemostasis 1991;21:278-85.
21. Mehta JL, Chen LY, Nichols WW, et al. Recombinant lys- plasminogen, but not glu-plasminogen, improves recombinant tissue-type plasminogen activator-induced coronary thrombolysis in dogs. J Am Coll Cardiol 1995;25:753-60.
22. Vatner SF, Franklin D, Van Citters RL. Simultaneous comparison and calibration of the Doppler and electromagnetic flow meters. J Appl Physiol 1970;29:907-15.
23. Rusby SJ, Mulvihill E, Rao D, et al. Expression of recombinant human plasminogen in mammalian cells is augmented by suppression of plasmin activity. J Biol Chem 1991;266: 15286-92.
24. Takada A, Watahiki Y, Takada Y. Release of N-terminal peptides from glu-plasminogen by plasmin in the presence of fibrin. Thromb Res 1986;41:819-27.
25. Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of ω-aminocarboxylic acids. Biochim Biophys Acta 1975;393:55-65.
26. Hoylaerts M, Rijken DC, Lijnen HR, Collen D. Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin. J Biol Chem 1982;257:2912-9.
27. Rånby M. Studies on the kinetics of plasminogen activation by tissue plasminogen activator. Biochim Biophys Acta 1982;704:461-9.
28. Watahiki Y, Scully MF, Kakkar VV. Potentiation by lys- plasminogen of clot lysis by single or two chain urokinase- type plasminogen activator or tissue-type plasminogen activator. Thromb Haemost 1989;61:502-6.
29. Nishino N, Kakkar V, Scully MF. Influence of intrinsic and extrinsic plasminogen upon the lysis of thrombi in vitro. Thromb Haemost 1991;66:672-7.
30. Suenson E, Bjerrum P, Holm A, et al. The role of fragment X polymers in the fibrin enhancement of tissue plasminogen activator-catalyzed plasmin formation. J Biol Chem 1990; 265:22228-37.
31. Taylor FBJ, Muller-Eberhard JH. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in aggregation and retraction of platelets. J Clin Invest 1970;49:2068-85.
32. Lockhart M, Comp PC, Taylor FBJ. Role of platelets in lysis of dilute plasma clots: requirement for metabolically active platelets. J Lab Clin Med 1979;94:285-94.
33. Carroll RC, Gerrard JM, Gilliam JM. Clot retraction facilitates clot lysis. Blood 1981;57:44-8.
34. Carroll RC, Dardcliffe RD, Taylor FBJ, Gerrard JM. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. J Lab Clin Med 1986;100:986-96.
35. Miles LA, Plow EP. Platelets bind plasminogen and potentiate its activation. Haemostasis 1984;14:48.
36. Falk E. Unstable angina with fatal outcome dynamic coronary thrombosis leading to infarction and/or sudden death: autopsy evidence of recurrent mural thrombosis with peripheral embolization culminating in total vascular occlusion. Circulation 1985;71:699-708.
37. Yasuda T, Gold HK, Leinbach RC, et al. Effect of reduced heparin on t-PA thrombolysis during platelet GPIIb/IIIa receptor blockade. Circulation 1990;82:276.
38. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chartman BR, Ross AM. A comparison between heparin and low dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323: 1433-7.
39. Patthy L. Evolution of blood coagulation and fibrinolysis. Fibrinolysis 1990;1:153-66.
40. Chen LY, Mehta JL. Lys- and glu-plasminogen potentiate the inhibitory effect of recombinant tissue plasminogen activator on human platelet aggregation. Thromb Res 1994;74: 555-63.
41. Bagge L, Bjork I, Saldeen T, Wallin R. Purification and characterization of an inhibitor of plasminogen activation from post-traumatic patients. Forensic Sci Int 1976;7:83-6.
42. 2-plasmin inhibitor. Thromb Res 1977;10:851-6.